Adjuvant chemotherapy for stage II colon cancer with poor prognostic features

Journal of Clinical Oncology

Volumn 29, Issue 25, 2011, Pages 3381-3388

  O'Connor, Erin S ^a   Greenblatt, David Yu ^a   LoConte, Noelle K ^a   Gangnon, Ronald E ^a   Liou, Jinn Ing ^a   Heise, Charles P ^a   Smith, Maureen A ^a  

^a UNIVERSITY OF WISCONSIN   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AGED; ANALYSIS OF VARIANCE; ARTICLE; CANCER ADJUVANT THERAPY; CANCER LOCALIZATION; CANCER STAGING; CANCER SURVIVAL; COLON ADENOCARCINOMA; COLON RESECTION; CONTROLLED STUDY; DATA BASE; DEMOGRAPHY; ETHNICITY; FEMALE; HUMAN; KAPLAN MEIER METHOD; MAJOR CLINICAL STUDY; MALE; MARRIAGE; MEDICARE; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGNOSIS; PROPORTIONAL HAZARDS MODEL;

ADENOCARCINOMA; ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; CHEMOTHERAPY, ADJUVANT; COLONIC NEOPLASMS; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MEDICARE; MIDDLE AGED; NEOPLASM STAGING; PROGNOSIS; SEER PROGRAM; SURVIVAL RATE; UNITED STATES;

EID: 80052735984     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2010.34.3426     Document Type: Article

References (40)

1. Efficacy of adjuvant fluorouracil and folinic acid in B2 colon cancer: International Multicentre Pooled Analysis of B2 Colon Cancer Trials (IMPACT B2) Investigators. J Clin Oncol 17:1356-1363, 1999
2. Gill S, Loprinzi CL, Sargent DJ, et al: Pooled analysis of fluorouracil-based adjuvant therapy for stage II and III colon cancer: Who benefits and by how much? J Clin Oncol 22:1797-1806, 2004 (Pubitemid 41095169)
3. Sargent D, Sobrero A, Grothey A, et al: Evidence for cure by adjuvant therapy in colon cancer: Observations based on individual patient data from 20,898 patients on 18 randomized trials. J Clin Oncol 27:872-877, 2009
4. Mamounas E, Wieand S, Wolmark N, et al: Comparative efficacy of adjuvant chemotherapy in patients with Dukes' B versus Dukes' C colon cancer: Results from four National Surgical Adjuvant Breast and Bowel Project adjuvant studies (C-01, C-02, C-03, and C-04). J Clin Oncol 17:1349-1355, 1999 (Pubitemid 29220839)
5. Sharif S, O'Connell MJ, Yothers G, et al: FOLFOX and FLOX regimens for the adjuvant treatment of resected stage II and III colon cancer. Cancer Invest 26:956-963, 2008
6. Wolmark N, Rockette H, Fisher B, et al: The benefit of leucovorin-modulated fluorouracil as postoperative adjuvant therapy for primary colon cancer: Results from National Surgical Adjuvant Breast and Bowel Project protocol C-03. J Clin Oncol 11:1879-1887, 1993 (Pubitemid 23304611)
7. Wolmark N, Rockette H, Mamounas E, et al: Clinical trial to assess the relative efficacy of fluorouracil and leucovorin, fluorouracil and levamisole, and fluorouracil, leucovorin, and levamisole in patients with Dukes' B and C carcinoma of the colon: Results from National Surgical Adjuvant Breast and Bowel Project C-04. J Clin Oncol 17:3553-3559, 1999 (Pubitemid 29517927)
8. Quasar Collaborative Group, Gray R, Barnwell J, et al: Adjuvant chemotherapy versus observation in patients with colorectal cancer: A randomised study. Lancet 370:2020-2029, 2007
9. André T, Boni C, Mounedji-Boudiaf L, et al: Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer. N Engl J Med 350:2343-2351, 2004 (Pubitemid 38702845)
10. Efficacy of adjuvant fluorouracil and folinic acid in colon cancer: International Multicentre Pooled Analysis of Colon Cancer Trials (IMPACT) investigators. Lancet 345:939-944, 1995
11. Wilkinson NW, Yothers G, Lopa S, et al: Long-term survival results of surgery alone versus surgery plus 5-fluorouracil and leucovorin for stage II and stage III colon cancer: Pooled analysis of NSABP C-01 through C-05 - A baseline from which to compare modern adjuvant trials. Ann Surg Oncol 17:959-966, 2010
12. Benson AB 3rd, Schrag D, Somerfield MR, et al: American Society of Clinical Oncology recommendations on adjuvant chemotherapy for stage II colon cancer. J Clin Oncol 22:3408-3419, 2004 (Pubitemid 41103700)
13. Schrag D, Rifas-Shiman S, Saltz L, et al: Adjuvant chemotherapy use for Medicare beneficiaries with stage II colon cancer. J Clin Oncol 20:3999-4005, 2002
14. Le Voyer TE, Sigurdson ER, Hanlon AL, et al: Colon cancer survival is associated with increasing number of lymph nodes analyzed: A secondary survey of intergroup trial INT-0089. J Clin Oncol 21:2912-2919, 2003 (Pubitemid 46621841)
15. Buyse M, Piedbois P: Should Dukes' B patients receive adjuvant therapy? A statistical perspective. Semin Oncol 28:20-24, 2001 (suppl 1)
16. NIH consensus conference: Adjuvant therapy for patients with colon and rectal cancer. JAMA 264:1444-1450, 1990
17. Quah HM, Chou JF, Gonen M, et al: Identification of patients with high-risk stage II colon cancer for adjuvant therapy. Dis Colon Rectum 51:503-507, 2008
18. National Cancer Institute: SEER Program Overview. http://www.seer.cancer. gov/about/
19. Warren J, Klabunde C, Schrag D, et al: Overview of the SEER-Medicare data: Content, research applications, and generalizability to the United States elderly population. Med Care 40:IV-3-18, 2002 (suppl 8)
20. Potosky AL, Riley GF, Lubitz JD, et al: Potential for cancer related health services research using a linked Medicare-tumor registry database. Med Care 31:732-748, 1993
21. Greenblatt DY, Weber SM, O'Connor ES, et al: Readmission after colectomy for cancer predicts one-year mortality. Ann Surg 251:659-669, 2010
22. Bradley CJ, Given CW, Dahman B, et al: Adjuvant chemotherapy after resection in elderly Medicare and Medicaid patients with colon cancer. Arch Intern Med 168:521-529, 2008 (Pubitemid 351547216)
23. Dobie SA, Baldwin LM, Dominitz JA, et al: Completion of therapy by Medicare patients with stage III colon cancer. J Natl Cancer Inst 98:610-619, 2006 (Pubitemid 43904844)
24. Ash AS, Ellis RP, Pope GC, et al: Using diagnoses to describe populations and predict costs. Health Care Financ Rev 21:7-28, 2000
25. Rosenbaum PR, Rubin DB: The central role of the propensity score in observational studies for causal effects. Biometrika 70:41-55, 1983
26. Rubin DB: Estimating causal effects from large data sets using propensity scores. Ann Intern Med 127:757-763, 1997
27. D'Agostino RJ: Propensity score methods for bias reduction in the comparison of a treatment to a non-randomized control group. Stat Med 17:2265-2281, 1998
28. Rubin D: The design versus the analysis of observational studies for causal effects: Parallels with the design of randomized trials. Stat Med 26:20-36, 2007
29. Zuckerman IH, Rapp T, Onukwugha E, et al: Effect of age on survival benefit of adjuvant chemotherapy in elderly patients with Stage III colon cancer. J Am Geriatr Soc 57:1403-1410, 2009
30. Cucino C, Buchner AM, Sonnenberg A: Continued rightward shift of colorectal cancer. Dis Colon Rectum 45:1035-1040, 2002
31. Saltzstein SL, Behling CA: Age and time as factors in the left-to-right shift of the subsite of colorectal adenocarcinoma: A study of 213,383 cases from the California Cancer Registry. J Clin Gastroenterol 41:173-177, 2007 (Pubitemid 46148659)
32. National Cancer Institute: SEER Stat Fact Sheets: Cancer of the Colon and Rectum. http://www.seer.cancer.gov/statfacts/html/colorect.html
33. Hershman DL, Buono D, McBride RB, et al: Influence of private practice setting and physician characteristics on the use of breast cancer adjuvant chemotherapy for elderly women. Cancer 115:3848-3857, 2009
34. Kim GP, Colangelo LH, Wieand HS, et al: Prognostic and predictive roles of high-degree microsatellite instability in colon cancer: A National Cancer Institute-National Surgical Adjuvant Breast and Bowel Project Collaborative Study. J Clin Oncol 25:767-772, 2007 (Pubitemid 350002875)
35. Douillard JY, Cunningham D, Roth AD, et al: Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: A multicentre randomised trial. Lancet 355:1041-1047, 2000 (Pubitemid 30162806)
36. Sinicrope FA, Sargent DJ: Clinical implications of microsatellite instability in sporadic colon cancers. Curr Opin Oncol 21:369-373, 2009
37. Ribic CM, Sargent DJ, Moore MJ, et al: Tumor microsatellite-instability status as a predictor of benefit from fluorouracil-based adjuvant chemotherapy for colon cancer. N Engl J Med 349:247-257, 2003 (Pubitemid 36859476)
38. Samowitz WS, Albertsen H, Herrick J, et al: Evaluation of a large, population-based sample supports a CpG island methylator phenotype in colon cancer. Gastroenterology 129:837-845, 2005 (Pubitemid 41242676)
39. Weisenberger DJ, Siegmund KD, Campan M, et al: CpG island methylator phenotype underlies sporadic microsatellite instability and is tightly associated with BRAF mutation in colorectal cancer. Nat Genet 38:787-793, 2006 (Pubitemid 43980599)
40. Oxaliplatin, leucovorin, and fluorouracil with or without bevacizumab in treating patients who have undergone surgery for stage II colon cancer. http://clinicaltrials.gov/ct2/results?term=NCT00217737